UPC Analytics
DEEN
Übersicht · Eingereicht: 3. Juli 2024

UPC_CFI_380/2024

FLUID DELIVERY DEVICE WITH TRANSCUTANEOUS ACCESS TOOL, INSERTION MECHANISM AND BLOOD GLUCOSE MONITORING FOR USE THEREWITH

Einstweilige MaßnahmenEinstweilige MaßnahmenMilan CDProvisional measuresCase Closed
Parteien

Kläger

  • Insulet Corporation
Vertreter: Marc Grunwald (Peterreins Schley)

Beklagte

  • EOFLOW Co., Ltd.
Vertreter: Mirko Weinert (Hoyng Rokh Monegier)
Richter
  • Andrea Postiglione
  • Anna-Lena Klein
  • Uwe Schwengelbeck
Patente
  • EP4201327
  • EP 4 201 327
CPC-Codes: A61M5/1723, A61M5/1452, A61M5/158, A61B5/14865, A61M5/14244, F04B9/02, A61B5/14532, A61M2230/201, A61M2005/14506, A61M5/14248, B65D83/761, A61M5/3291

Sektor: Packaging & Conveying

Ausgang
PI abgelehnt
Eingereicht: 3. Juli 2024
Erste Entscheidung:
Sprache: English

The Milan Central Division rejected Insulet Corporation's application for a preliminary injunction against EOFLOW Co., Ltd. for alleged infringement of EP 4 201 327 (insulin pump). The Court held that the applicant had not established with sufficient certainty that the patent was valid (particularly claim 1 which appeared to lack novelty or inventive step over the prior art). The auxiliary request to amend the patent under R. 30.2 RoP was inadmissible in provisional measures proceedings given the requirement for expediency and the adversarial principle. Insulet was ordered to bear the costs; value in dispute EUR 2,500,000; cost ceiling EUR 400,000.

Im UPC-Register öffnen